The FDA's approval of oral GLP-1s marks a significant shift in drug formulation and analytical complexity for developers.
2
Oral GLP-1s require more rigorous stability data, impurity profiling, and stress testing compared to injectable formulations.
3
Analytical methods must evolve to address new impurity challenges, necessitating advanced techniques like multi-dimensional chromatography and high-resolution mass spectrometry.
4
Failure to fully understand impurity profiles can lead to reduced drug efficacy and regulatory delays, posing significant business risks.
5
Future GLP-1 analysis will focus on automation, higher-throughput workflows, and closer collaboration between formulation scientists and analytical chemists.
